FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

MONDAY, Jan. 23, 2023 -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The approval was...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news